Research Article: Tyrosine Kinase Inhibitors Plus Anti-PD- Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
Abstract:
Hepatocellular carcinoma (HCC), which accounts for approximately % of all cases, is the most common pathological type of primary liver cancer. Liver resection is the first choice of treatment for patients with early stage HCC and is associated with a -year survival rate of more than %., Transarterial and systemic therapies are recommended for patients at intermediate or advanced stages. Common transarterial therapies include transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC). TACE is a therapy consisting of intra-arterial chemotherapy and selected embolization, whereas HAIC is an interventional therapy without using embolic materials via the hepatic arteries. TACE and HAIC both exert promising anti-tumor effects on unresectable HCC, with a disease control rate (DCR) of .% for HAIC and a -year survival rate of .% for TACE.,
Introduction:
Hepatocellular carcinoma (HCC), which accounts for approximately % of all cases, is the most common pathological type of primary liver cancer. Liver resection is the first choice of treatment for patients with early stage HCC and is associated with a -year survival rate of more than %. , Transarterial and systemic therapies are recommended for patients at intermediate or advanced stages. Common transarterial therapies include transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC).…
Read more